Nurix Therapeutics, Inc. (NRIX) Soars 14.5%: Is Further Upside Left in the Stock?Zacks Investment Research • 05/31/22
Nurix Therapeutics Announces Participation in the 2022 RBC Capital Markets Global Healthcare ConferenceGlobeNewsWire • 05/11/22
Nurix Therapeutics Presents New Preclinical Data Supporting NX-2127 and DeTIL-0255 Clinical Programs at the American Association for Cancer Research Annual MeetingGlobeNewsWire • 04/08/22
Nurix Therapeutics Reports Fiscal First Quarter 2022 Financial Results and Provides a Corporate UpdateGlobeNewsWire • 04/07/22
Nurix Therapeutics Announces Participation in the 21st Annual Needham Virtual Healthcare ConferenceGlobeNewsWire • 04/04/22
Nurix Therapeutics Awarded Innovation Passport for Entry into Innovative Licensing and Access Pathway (ILAP) in the United Kingdom for NX-1607GlobeNewsWire • 03/29/22
Nurix Therapeutics to Present Preclinical Data from Its Novel BTK Degrader (NX-2127) and CBL-B Inhibitor (NX-0255) Programs at the American Association for Cancer Research Annual MeetingGlobeNewsWire • 03/08/22
Nurix Therapeutics Announces Participation in the 11th Annual SVB Leerink Global Healthcare ConferenceGlobeNewsWire • 02/10/22
Nurix Therapeutics Reports Fourth Quarter and Fiscal Year 2021 Financial Results and Provides a Corporate UpdateGlobeNewsWire • 01/27/22
Nurix Therapeutics Advances Clinical and Preclinical Pipeline and Outlines 2022 CatalystsGlobeNewsWire • 01/10/22
Nurix Therapeutics to Present at 40th Annual J.P. Morgan Healthcare ConferenceGlobeNewsWire • 01/03/22
Nurix Therapeutics Announces Regulatory Clearance to Initiate Phase 1 Clinical Trial of NX-5948 and Presents New Preclinical Data at the American Society of Hematology Annual MeetingGlobeNewsWire • 12/12/21
Nurix Therapeutics Announces IND clearance for DeTIL-0255, a drug-enhanced autologous T cell therapy for the potential treatment of a variety of solid tumorsGlobeNewsWire • 11/12/21
Nurix Therapeutics Presents Beneficial Effects of CBL-B Inhibition on Human Tumor Infiltrating Lymphocytes at SITC ConferenceGlobeNewsWire • 11/12/21
Nurix Therapeutics Announces Initial Data from the First Phase 1a Dose Escalation Trial of NX-2127 in Patients with Relapsed or Refractory B Cell MalignanciesGlobeNewsWire • 10/27/21
Nurix Therapeutics to Present Initial Target Degradation Data from First Phase 1 Trial of NX-2127 in B Cell Malignancies at the 4th Annual Targeted Protein Degradation SummitGlobeNewsWire • 10/26/21
Nurix Therapeutics, Inc. (NRIX) Reports Q3 Loss, Tops Revenue EstimatesZacks Investment Research • 10/14/21
Nurix Therapeutics Reports Third Quarter Fiscal 2021 Financial Results and Provides a Corporate UpdateGlobeNewsWire • 10/14/21
Nurix Therapeutics Expands its Board of Directors with the Addition of Two Industry LeadersGlobeNewsWire • 09/30/21
Nurix Therapeutics Reports Second Quarter Fiscal 2021 Financial Results and Provides a Corporate UpdateGlobeNewsWire • 07/13/21
Nurix Therapeutics Announces Appointment of Stefani A. Wolff as Chief Operating Officer and Executive Vice President, Product DevelopmentGlobeNewsWire • 06/21/21